- Published on
Ophthalmology – Chronic Iridocyclitis
Chronic iridocyclitis is a form of anterior uveitis characterized by inflammation of the iris and ciliary body that persists for more than six weeks. It typically has an insidious onset and may be asymptomatic in early stages, leading to delayed diagnosis. Bilateral involvement is common, especially in cases associated with systemic disease.
Epidemiologically, idiopathic chronic iridocyclitis is relatively rare, with an incidence of approximately 1 case per 300,000 population and a prevalence of about 1 case per 14,000. It is frequently associated with chronic systemic inflammatory or autoimmune conditions, particularly in pediatric populations such as those with juvenile idiopathic arthritis.
Risk factors include systemic inflammatory diseases such as juvenile idiopathic arthritis, sarcoidosis, ankylosing spondylitis, inflammatory bowel disease, and infections like tuberculosis or syphilis. Genetic predisposition has been noted, particularly with certain HLA subtypes. Screening is important in at-risk populations, especially children with autoimmune conditions, as the disease may be clinically silent.
The pathophysiology involves breakdown of the blood–aqueous barrier with infiltration of leukocytes into the anterior chamber. This results in persistent inflammation, which can lead to structural damage over time if untreated.
Clinically, many patients are asymptomatic until complications develop. When symptoms occur, they may include mild redness, blurred vision, or photophobia. Examination findings include anterior chamber cells and flare, keratic precipitates on the corneal endothelium, and iris changes. Specific patterns such as stellate keratic precipitates in Fuchs heterochromic iridocyclitis or “mutton-fat” keratic precipitates in granulomatous disease can provide diagnostic clues. Chronic inflammation may also lead to posterior synechiae, band keratopathy, elevated intraocular pressure, or hypotony.
Diagnosis is clinical but supported by targeted laboratory and imaging investigations based on suspected underlying causes. These may include blood tests (e.g., ANA, ACE, infectious serologies), chest imaging for sarcoidosis or tuberculosis, and occasionally anterior chamber sampling for PCR analysis in unclear cases. Regular slit-lamp examinations are essential for monitoring, particularly in asymptomatic high-risk patients.
Management primarily involves anti-inflammatory therapy. First-line treatment includes topical corticosteroids such as prednisolone acetate and cycloplegic agents to relieve pain and prevent synechiae. Elevated intraocular pressure is treated with appropriate glaucoma medications. In more severe or refractory cases, periocular or intravitreal corticosteroids may be used.
For bilateral or systemic disease, systemic corticosteroids or immunosuppressive agents may be required. Steroid-sparing agents such as methotrexate, azathioprine, or biologic therapies are often used for long-term control, typically in collaboration with rheumatology or other specialists.
Prognosis varies depending on the underlying cause and timeliness of treatment. The disease often follows a relapsing-remitting course, and delayed diagnosis can result in significant visual impairment. Early detection and appropriate management are key to preserving vision.
Complications include cataract formation, glaucoma, cystoid macular edema, band keratopathy, and posterior synechiae. These complications are major contributors to vision loss in chronic iridocyclitis and highlight the importance of regular follow-up and early intervention.
0 Comments
